Prostate Cancer

Prostate cancer is a malignant growth that develops in the tissues of the prostate—a small, walnut-sized gland in men located just below the bladder that produces seminal fluid. It is one of the most significant oncological challenges globally. Clinical evidence shows that while many prostate cancers grow slowly and remain confined to the gland for years, other types are aggressive and can spread (metastasize) rapidly to distant sites such as the bones and lymph nodes.

Prostate cancer represents roughly 14.2% of all diagnosed cancers in men globally. According to the World Health Organization (WHO) and recent epidemiological reviews, it is the most commonly diagnosed cancer among men in 118 countries. Global incidence is projected to rise steadily, with estimates suggesting that cases may nearly double from 1.47 million in 2022 to approximately 2.88 million by 2050 due to an aging population and changing diagnostic capabilities.

• Age: The primary risk factor; clinical incidence rises sharply after the age of 50.
• Family History & Genetics: Men with a first-degree relative (father or brother) diagnosed with prostate cancer face a significantly higher risk. Specific inherited gene mutations, such as BRCA1 or BRCA2, are also linked to increased vulnerability.
• Ethnicity: Epidemiological data show a higher incidence and mortality rate among Black men compared to Caucasian or Asian men.
• Diet and Lifestyle: High intake of processed meats and dairy products, combined with physical inactivity, may correlate with a higher risk of developing advanced forms of the disease.

Early-stage prostate cancer frequently causes no noticeable symptoms. When symptoms do occur, they may include:
• Difficulty initiating urination or a weak, interrupted urinary stream.
• Frequent urination, particularly at night (nocturia).
• Pain or burning during urination.
• Blood in the urine (hematuria) or semen.
• Persistent pain in the back, hips, or pelvis (often indicative of advanced or metastatic disease).
Clinical Note: Many of these symptoms overlap with non-cancerous conditions like Benign Prostatic Hyperplasia (BPH). Prompt medical evaluation is necessary to determine the underlying cause.

Diagnosis typically involves a multi-step clinical evaluation:
• Prostate-Specific Antigen (PSA) Blood Test: Elevated PSA levels may indicate prostate abnormalities, though they are not specific to cancer.
• Digital Rectal Examination (DRE): A physical assessment to detect structural changes or nodules.
• Multiparametric MRI and Tissue Biopsy: Advanced imaging and core needle biopsies are used to confirm malignancy and assign a Gleason Score, which measures tumor aggressiveness.
Management strategies depend on the disease stage and patient health profile. Studies have shown that localized, low-risk tumors may be successfully managed through active surveillance (regular monitoring via PSA and biopsies without immediate intervention). Active treatment choices include surgery (radical prostatectomy), radiation therapy (external beam or brachytherapy), androgen deprivation therapy (ADT) to suppress hormone production, and chemotherapy or targeted biological therapies for advanced disease stages. Treatment benefits must be carefully weighed against potential side effects, such as urinary incontinence and erectile dysfunction.